FDA Approves Basaglar® (insulin glargine injection), a Long-Acting Insulin Treatment
INDIANAPOLIS and RIDGEFIELD, Conn., Dec. 16, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Basaglar® (insulin glargine injection) 100 units/mL. BASAGLAR is a long-acting insulin with an identical amino acid sequence to Lantus®, another U-100 insulin glargine. It is delivered via the prefilled BASAGLAR KwikPen®.
BASAGLAR is indicated to control high blood sugar in adults and children with type 1 diabetes and adults with type 2 diabetes. BASAGLAR should not be used to treat diabetic ketoacidosis. BASAGLAR should not be used during episodes of low blood sugar (hypoglycemia) or in people with an allergy to insulin glargine or any of the ingredients in BASAGLAR.
"Lilly has a long history of developing and manufacturing insulin, having introduced the world's first commercial insulin more than 90 years ago," said David Kendall, MD, vice president, Global Medical Affairs, Lilly Diabetes. "BASAGLAR will be a welcome addition to our insulin and alliance portfolios, offering an option for people with diabetes who may need a long-acting insulin."
The BASAGLAR FDA approval is based, in part, upon an extensive clinical development program. The submission included results from pharmacokinetic and pharmacodynamic studies, as well as Phase III studies in people with type 1 and type 2 diabetes comparing the safety and efficacy of BASAGLAR to U.S.- and non-U.S.-approved Lantus.
The FDA approval follows BASAGLAR's tentative U.S. approval in August 2014, which was contingent upon patent litigation resolution. Per the settlement agreement with Sanofi, BASAGLAR will be available in the U.S. starting on December 15, 2016.
"The BASAGLAR FDA approval marks the first insulin therapy to be approved in the U.S. as part of our alliance with Lilly and broadens our portfolio of treatment options for people with type 1 and type 2 diabetes," said Paul Fonteyne, president and CEO, BIPI. "We remain committed to the care of people with diabetes and look forward to a successful U.S. launch of BASAGLAR."
This latest regulatory approval is the 11th for BASAGLAR worldwide, with launches taking place in several countries this year, including under the trade name Abasaglar® in Europe.
BASAGLAR Indication
BASAGLAR is a long-acting, man-made insulin indicated to control high blood sugar in adults and children with type 1 diabetes and adults with type 2 diabetes.
BASAGLAR should not be used to treat diabetic ketoacidosis.
About Diabetes
Approximately 29 million Americans1 and an estimated 415 million people worldwide2 have type 1 or type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases.1 Diabetes is a chronic condition that occurs when the body either does not properly produce, or use, the hormone insulin.2
Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in diabetes that centers on compounds representing several of the largest diabetes treatment classes. The alliance leverages the strengths of two of the world's leading pharmaceutical companies. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributed to the alliance. Find out more about the alliance at www.boehringer-ingelheim.com or www.lilly.com.
About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.
Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with 146 affiliates and more than 47,000 employees. Since its founding in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel treatments for human and veterinary medicine.
Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and families. Our employees create and engage in programs that strengthen our communities. To learn more about how we make more health for more people, visit our Corporate Social Responsibility Report.
In 2014, Boehringer Ingelheim achieved net sales of about $16.96 billion dollars (13.3 billion euros). R&D expenditure corresponds to 19.9 percent of its net sales.
For more information please visit www.us.boehringer-ingelheim.com, or follow us on Twitter @BoehringerUS.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels.
http://www.prnewswire.com/
